125872-97-1

Basic information

• Product Name: 3-AMINOCINNAMIC ACID ETHYL ESTER
• Synonyms: ETHYL 3-AMINOCINNAMATE;3-AMINOCINNAMIC ACID ETHYL ESTER;Ethyl (E)-3-(3-aminophenyl)-2-propenoate;Ethyl trans-3-aminocinnamate;Ethyl (2E)-3-(3-aminophenyl)prop-2-enoate
• CAS NO: 125872-97-1
• Molecular Formula: C₁₁H₁₃NO₂
• Molecular Weight: 191.23
• Product Categories: Aromatic Cinnamic Acids, Esters and Derivatives
• Mol File: 125872-97-1.mol
• Article Data: 10

Chemical Properties

• Melting Point: 48 °C
• Boiling Point: 348.3±25.0 °C(Predicted)
• Appearance: /
• Density: 1.130±0.06 g/cm3(Predicted)
• PKA: 3.63±0.10(Predicted)
• CAS DataBase Reference: 3-AMINOCINNAMIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINOCINNAMIC ACID ETHYL ESTER(125872-97-1)
• EPA Substance Registry System: 3-AMINOCINNAMIC ACID ETHYL ESTER(125872-97-1)

Safety Data

• Hazardous Substances Data: 125872-97-1(Hazardous Substances Data)

Usage

General Description

3-Aminocinnamic acid ethyl ester is a chemical compound with the molecular formula C11H13NO2. It is a derivative of cinnamic acid and contains an ethyl ester group and an amino group. 3-AMINOCINNAMIC ACID ETHYL ESTER is commonly used in the synthesis of pharmaceuticals and organic compounds due to its ability to react with other chemicals to form diverse products. It is also utilized as a reagent in organic chemistry research and as an intermediate in the production of various drugs. Additionally, 3-aminocinnamic acid ethyl ester has been studied for its potential pharmacological properties, including its anti-inflammatory and anti-cancer activities, making it a molecule of interest in medicinal chemistry.

Upstream product

• 598-21-0 2-Bromoacetyl bromide 
• 100-61-8 N-methylaniline 
• 626-01-7 3-Iodoaniline 
• 140-88-5 ethyl acrylate 
• 555-68-0 (E)-3-Nitrocinnamic acid 
• 59114-88-4 ethyl (2E)-3-(3-bromophenyl)prop-2-enoate 
• 3132-99-8 m-bromobenzoic aldehyde 
• 99-61-6 3-nitro-benzaldehyde 
• 621-19-2 (E)-ethyl 3-(3-nitrophenyl)acrylate 
• 555-68-0 m-Nitrocinnamic Acid 
• 5396-71-4 ethyl 3-(3-nitrophenyl)acrylate 

Downstream Products

• 855227-71-3 3-(3-amino-phenyl)-4-cyano-4-phenyl-butyric acid ethyl ester 
• 1109237-20-8 C₂₀H₁₉N₃O₄ 
• 1109237-18-4 C₂₂H₂₁N₃O₅ 
• 1109237-32-2 C₂₃H₂₁N₃O₆ 
• 1254211-21-6 ethyl 4-(3-aminophenyl)-5-methyl-1H-pyrrole-3-carboxylate 
• 1261078-79-8 (E)-3-{3-[N-(quinoxalin-2-yl)amino]phenyl}acrylic acid ethyl ester 
• 1261078-69-6 (E)-ethyl 3-(3-(6-nitroquinoxalin-3-ylamino)phenyl)acrylate 
• 1428236-99-0 C₁₉H₁₆N₂O₅ 
• 1613142-57-6 (E)-ethyl 3-(3-(p-toluenesulfonamido)phenyl)acrylate 
• 1613142-59-8 (E)-ethyl 3-(3-(3-phenylthioureido)phenyl)acrylate 

Relevant articles and documents

5,6-dihydropyrrolo[2,1-a]isoquinolines as alternative of new drugs with cytotoxic activity

In this study, the pyrrolo[2,1-a]isoquinolines 4a–n were synthesized in good yields in a three steps synthesis from the corresponding α,β-unsaturated esters starting materials. These compounds were tested on six human cancer cells lines to measure the cyt

N, N-disubstituted benzo-nitrogen heterocycles-2-amine compound and use thereof

The invention mainly relates to an N,N-double substituted benzoazacyclo-2-amide compound and an application thereof. The N,N-double substituted benzoazacyclo-2-amide compound is a compound shown as formula I or a salt formed by a medical acid or alkali. The compound provided by the invention has strong inhibition activity on RhoA protease which is tightly related with cardiovascular and cerebrovascular diseases. The compound provided by the invention is hopeful to be developed into a RhoA protease small-molecule inhibitor type cardiovascular and cerebrovascular disease treatment medicine.

Development of second-generation small-molecule RhoA inhibitors with enhanced water solubility, tissue potency, and significant in vivo efficacy

RhoA, a member of the Rho GTPases, is involved in a variety of cellular functions and could be a suitable therapeutic target for the treatment of cardiovascular diseases. However, few small-molecule RhoA inhibitors have been reported. Based on our previously reported lead compounds, 32 new 2-substituted quinoline (or quinoxaline) derivatives were synthesized and tested in biological assays. Six compounds showed high RhoA inhibitory activities, with IC50 values of 1.17-1.84 μM. Among these, (E)-3-(3-(ethyl(quinolin-2-yl)amino)phenyl)acrylic acid (26b) and (E)-3-(3-(butyl(quinolin-2-yl)amino)phenyl)acrylic acid (26d) demonstrated noticeable vasorelaxation effects against phenylephrine-induced contraction in thoracic aorta artery rings, and compound 26b had good water solubility and showed significant in vivo efficacy, which was similar to that of 5-(1,4-diazepane-1-sulfonyl)isoquinoline (fasudil) in a subarachnoid hemorrhage-cardiovascular model. To the best of our knowledge, compound 26b is the first example of a small-molecule RhoA inhibitor with potent in vivo efficacy, which could serve as a good lead for designing cardiovascular agents.